Novo Nordisk A/S (NVO) — closed signal from March 25, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on June 23, 2026.
Predicted vs. what happened
NVO price · publication thesis → realized outcomesplit-adjusted
$36.00 – $38.50Entry zone — fair-value band
$37.25Published — price the day we called it
$42.84Target — the price the thesis aimed for
$47.79Peak — highest point inside the window, not a realized return
$47.42Window close — end-of-window price, context only
What happened
Target reached
Reached its target in 36 days.
Peak price
$47.79
peak on May 11, 2026 — not a realized returnPeak gain
+28.3%
peak, from the publication priceWindow close
$47.42
end-of-window price, context onlyDays to target
36
Window
March 25, 2026 – June 23, 2026
The thesis — published March 25, 2026
Predicted growth
+15%
over the measurement windowTarget price
$42.84
the price the thesis aimed forEntry zone
$36.00 – $38.50
the fair-value band we waited forPrice at publication
$37.25
published March 25, 2026Confidence
80%
how strongly the data lined upTimeframe
Short-term (0–3 months)
Novo Nordisk looks like a defensive short-term opportunity because worries in the market are already reflected in the price while the company still makes strong profits. New drug trial results for obesity and diabetes keep interest alive, and the shares seem deeply sold off rather than permanently damaged. The setup can perform even if overall markets are uneven.
Primary drivers
- Trial updates for obesity and diabetes keep the growth story active
- Consistently profitable business with defensive qualities
- Big selloff creates space for price to bounce back
- Lower valuation reduces need for perfect future growth
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.